Last checked at 12 Jun 2018 15:47
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
12 June 2018
Accrol Group Holdings plc
(AIM: ACRL)
Directors' Dealings
Accrol Group Holdings plc (the "Company" or "Accrol"), the AIM-listed leading independent tissue converter, is pleased to announce that, as part of the recent open offer announced on 7 June 2018, certain directors of Accrol have purchased in aggregate 81,807 ordinary shares of £0.001 each ("Ordinary Shares") at a price of 15p per Ordinary Share as set out below.
Number of Shares |
Value of Shares |
Resulting Shareholding | Percentage of Enlarged Share Capital | ||
Name | Title | ||||
Daniel Wright | Executive Chairman | 71,807 | £10,771.05 | 1,820,308 | 0.93% |
Gareth Jenkins | Chief Executive Officer | 10,000 | £1,500.00 | 610,000 | 0.31% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | i) Dan Wright ii) Gareth Jenkins
| |
2 | Reason for the notification | ||
a) | Position/status | i) Executive Chairman ii) Chief Executive Officer
| |
b)
| Initial notification /Amendment | Initial notification | |
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Accrol Group Holdings plc | |
b) | LEI | 213800MC56M5G69RJ226 | |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.001
ISIN: GB00BZ6VT592 | |
b) | Nature of the transaction | Purchase of Ordinary Shares | |
c) | Price(s) and volume(s) | Price(s) 15p
| Volume(s) i) 71,807 ii) 10,000
|
d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | |
e) | Date of the transaction | 8 June 2017 | |
f) | Place of the transaction | London Stock Exchange, AIM | |
Enquiries:
For further information, please contact: |
|
|
|
Accrol Group Holdings plc |
|
Gareth Jenkins, Chief Executive Officer | +44 (0) 1254 278 844 |
Steve Townsley, Chief Finance Officer | +44 (0) 1254 278 844 |
|
|
Zeus Capital Limited (Nominated Adviser & Broker) |
|
Dan Bate / Andrew Jones | +44 (0) 161 831 1512 |
Dominic King / John Goold | +44 (0) 203 829 5000 |
|
|
Belvedere Communications Limited |
|
Cat Valentine (cvalentine@belvederepr.com) | +44 (0) 7715 769 078 |
Llew Angus (langus@belvederepr.com) | +44 (0) 7407 023 147 |
Notes to Editors
Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK.
Accrol operates from three sites:
· A manufacturing, storage and distribution facility in Blackburn;
· A facial tissue plant, also in Blackburn; and
· A manufacturing, storage and distribution facility in Leyland.